Related references
Note: Only part of the references are listed.Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Nicolas Huyghe et al.
GASTROENTEROLOGY REPORT (2020)
MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer
Yi-Lin Chen et al.
CELL BIOLOGY INTERNATIONAL (2020)
Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Mark Yarchoan et al.
CANCER MEDICINE (2020)
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al.
NATURE MEDICINE (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients
Jacqueline Wyss et al.
CLINICAL COLORECTAL CANCER (2019)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort
Ann C. Eriksen et al.
BMC CANCER (2019)
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy
Tsung-Wei Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability high (MSI-H) tumors.
Neil Howard Segal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
Eric Xueyu Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
Hsiang-Ling Ho et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
Philippe Alexandre Cassier et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.
Niels Halama et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).
Joleen Marie Hubbard et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells
Jenny Lazarus et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer
Charalampos S. Floudas et al.
CLINICAL COLORECTAL CANCER (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells
Takato Yomoda et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms
Tsuyoshi Hamada et al.
JOURNAL OF PATHOLOGY (2019)
Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.
Arta Monjazeb et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Manish R. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Anti-PD-1 antibody cetrelimab (JNJ-63723283) in patients with advanced cancers: Updated phase I/II study results.
Piotr Rutkowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer
Benedikt Martin et al.
VISCERAL MEDICINE (2019)
Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer
Tumenjin Enkhbat et al.
ANTICANCER RESEARCH (2018)
Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis
Kyu Sang Lee et al.
CANCER SCIENCE (2018)
Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer
Atsushi Ogura et al.
EUROPEAN JOURNAL OF CANCER (2018)
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine
Shuji Ogino et al.
GUT (2018)
CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer
Soo Jung Lee et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
Eiji Shinozaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
Rachel E. Sanborn et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
Nilofer Saba Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
RAS status and neoadjuvant chemotherapy impact CD8+cells and tumor HLA class I expression in liver metastatic colorectal cancer
Fanny Ledys et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy
Chih-Yang Huang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer
Xiao-Li Wei et al.
JOURNAL OF CANCER (2018)
A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC.
Patrick Mckay Boland et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Noboru Yamamoto et al.
INVESTIGATIONAL NEW DRUGS (2017)
Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC)
Howard S. Hochster et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status
Tsuyoshi Hamada et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3
T. J. Miller et al.
PATHOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
A Blueprint to Advance Colorectal Cancer Immunotherapies
Dung T. Le et al.
CANCER IMMUNOLOGY RESEARCH (2017)
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Dagmar Kollmann et al.
ONCOIMMUNOLOGY (2017)
Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy
Lingdong Shao et al.
CANCER MANAGEMENT AND RESEARCH (2017)
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Safi Shanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) plus tremelimumab (TRE) in patients with advanced solid tumors.
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer
Kyu Sang Lee et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer
Shigehiro Koganemaru et al.
CANCER SCIENCE (2017)
Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.
James J. Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
Jung Ho Kim et al.
BRITISH JOURNAL OF CANCER (2016)
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis
Markus Hecht et al.
EUROPEAN JOURNAL OF CANCER (2016)
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy
Susumu Saigusa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lik Hang Lee et al.
MODERN PATHOLOGY (2016)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
Yaqi Li et al.
MOLECULAR CANCER (2016)
Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients.
Neil Howard Segal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
Raoul A. Droeser et al.
EUROPEAN JOURNAL OF CANCER (2013)
B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells
Sheng-Jia Shi et al.
PLOS ONE (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Douglas G. Altman et al.
PLOS MEDICINE (2012)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
